Group 1 - The A-share market saw a significant decline in commercial aerospace stocks in the afternoon session [1] - Tianli Composite dropped over 11%, while Shenjian Co. approached the daily limit down [1] - Other notable declines included Superjet Co. down over 9%, Aerospace Hanyu down over 8%, and several companies including Paker New Materials and Goldwind Technology down over 7% [1] Group 2 - Companies such as Chuangyuan Technology, Zhaobiao Co., Jiangshun Technology, and others experienced declines exceeding 6% [1]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Dabo Medical (002901) as of December 29, 2025, showing a slight decline in stock price and notable changes in capital flow [1][2]. Group 2 - Dabo Medical reported a main revenue of 1.876 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders for the same period was 425 million yuan, up 77.03% year-on-year, while the net profit after deducting non-recurring items was 346 million yuan, an increase of 63.99% [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 666 million yuan, reflecting a year-on-year growth of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, up 77.49% year-on-year, and the net profit after deducting non-recurring items was 123 million yuan, increasing by 38.44% [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan, while the gross profit margin is 71.23% [2]. - Dabo Medical specializes in the production, research, and sales of high-value medical consumables [2]. Group 3 - Over the last 90 days, one institution has given a buy rating for Dabo Medical [3]. - The capital flow data indicates a net outflow of 9.4984 million yuan from main funds, accounting for 12.08% of the total transaction amount, while retail investors saw a net inflow of 8.1568 million yuan, representing 10.37% of the total transaction amount [1].

Core Viewpoint - The stock of Dabo Medical (002901) shows a slight increase in price and mixed capital flow, indicating varying investor sentiment and potential opportunities for analysis [1][2]. Group 1: Stock Performance - As of December 23, 2025, Dabo Medical's stock closed at 49.61 yuan, with a minor increase of 0.1% and a turnover rate of 0.6% [1]. - The trading volume on December 23 was 17,400 hands, with a total transaction value of 86.5954 million yuan [1]. Group 2: Capital Flow Analysis - On December 23, the net inflow of main funds was 2.6422 million yuan, accounting for 3.05% of the total transaction value, while retail investors saw a net inflow of 3.3368 million yuan, representing 3.85% [1][2]. - In contrast, speculative funds experienced a net outflow of 5.979 million yuan, which is 6.9% of the total transaction value [1][2]. Group 3: Financial Metrics and Industry Ranking - Dabo Medical's total market capitalization is 20.54 billion yuan, significantly higher than the industry average of 10.786 billion yuan, ranking 10th out of 125 in the medical device sector [3]. - The company reported a net profit of 425 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 77.03%, with a gross margin of 71.23% [3]. - The company's return on equity (ROE) stands at 12.83%, which is substantially higher than the industry average of 0.23%, ranking 7th out of 125 [3].

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Dabo Medical (002901) as of December 18, 2025, with a closing price of 48.87 yuan, reflecting a 0.74% increase [1] - Dabo Medical's main business involves the production, research, and sales of high-value medical consumables [2] - The company reported a total revenue of 1.876 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 22.69%, and a net profit attributable to shareholders of 425 million yuan, up 77.03% year-on-year [2] Group 2 - In Q3 2025, Dabo Medical achieved a quarterly revenue of 666 million yuan, which is a 17.82% increase compared to the same quarter last year, and a net profit of 180 million yuan, reflecting a 77.49% year-on-year growth [2] - The company's financial metrics include a debt ratio of 24.53%, investment income of 5.81 million yuan, financial expenses of -23.87 million yuan, and a gross profit margin of 71.23% [2] - Over the last 90 days, one institution has given a buy rating for Dabo Medical [3]

中国经济网北京12月17日讯 大博医疗(002901.SZ)昨日晚间发布关于持股5%以上股东股份变动触及1% 整数倍暨减持完成的公告。近日，公司收到持股5%以上股东大博医疗国际投资有限公司（以下简称"大博国 际"）出具的《关于股份变动触及1%整数倍暨减持计划实施完成的告知函》。 公司于近日收到股东大博国际的通知，获悉其于2025年12月5日至2025年12月16日期间通过证券交易所 的集中竞价交易和大宗交易方式合计减持公司股份6,300,959股，占公司总股本比例为1.52%。本次减持后， 大博国际及其一致行动人合计持有公司股份340,513,152股，持股比例由83.77%下降至82.25%（占公司总股 本比例），权益变动触及1%的整数倍。 2025年10月31日至2025年12月16日，大博国际合计减持股数为8,268,959股。经计算，大博国际减持金 额合计3.88亿元。 大博医疗2024年年报显示，公司实际控制人为林志雄及林志军。林志雄和林志军为同胞兄弟，赵少梅 为林志军配偶的母亲。大博国际的实际控制人为林志军。 大博医疗于2017年在深交所主板上市，公司2017年9月12日披露的招股书显示，大博国际 ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Dabo Medical (002901) as of December 16, 2025, with a closing price of 49.05 yuan, reflecting a slight increase of 0.22% [1] - The company reported a main revenue of 1.876 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 22.69% [2] - The net profit attributable to shareholders for the same period was 425 million yuan, showing a significant year-on-year growth of 77.03% [2] Group 2 - In Q3 2025, Dabo Medical achieved a quarterly main revenue of 666 million yuan, which is a 17.82% increase compared to the same quarter last year [2] - The company's net profit for Q3 2025 was 180 million yuan, marking a year-on-year increase of 77.49% [2] - The company has a debt ratio of 24.53% and a gross profit margin of 71.23%, indicating a strong financial position [2]

格隆汇12月16日丨大博医疗(002901.SZ)公布，公司于近日收到股东大博国际的通知，获悉其于2025年 12月5日至2025年12月16日期间通过证券交易所的集中竞价交易和大宗交易方式合计减持公司股份 6,300,959股，占公司总股本比例为1.52%。本次减持后，大博国际及其一致行动人合计持有公司股份 340,513,152股，持股比例由83.77%下降至82.25%（占公司总股本比例），权益变动触及1%的整数倍。 ...

暨减持完成的公告 股东大博医疗国际投资有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002901 证券简称：大博医疗 公告编号：2025-054 大博医疗科技股份有限公司 关于持股 5%以上股东股份变动触及 1%整数倍 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日披露 了《关于持股 5%以上股东股份减持计划的预披露公告》（公告编号：2025-033）、 2025 年 11 月 4 日披露了《关于持股 5%以上股东减持股份触及 1%整数倍》（公 告编号：2025-049）。近日，公司收到持股 5%以上股东大博医疗国际投资有限 公司（以下简称"大博国际"）出具的《关于股份变动触及 1%整数倍暨减持计 划实施完成的告知函》。现将相关情况公告如下： 一、股份变动触及 1%整数倍的情况 公司于近日收到股东大博国际的通知，获悉其于 2025 年 12 月 5 日至 2025 年12月16日期间通过证券交易所的集中竞价交易和大宗交易方式合 ...

两融数据显示，该股最新融资余额为1.37亿元，近5日增加592.92万元，增幅为4.52%。 据天眼查APP显示，大博医疗科技股份有限公司成立于2004年08月12日，注册资本41401.9506万人民 币。（数据宝） 大博医疗12月15日大宗交易平台出现一笔成交，成交量520.00万股，成交金额2.44亿元，大宗交易成交 价为47.00元，相对今日收盘价折价3.96%。该笔交易的买方营业部为中信证券股份有限公司厦门分公 司，卖方营业部为中信证券股份有限公司厦门分公司。 12月15日大博医疗大宗交易一览 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为3.35亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | 520.00 | 24440.00 | 47.00 | -3.96 | 中信证券股份有限公 | 中信证券股份有限公 | | | | | | 司厦门分公司 | 司厦门分公司 | 证券时报·数据宝 ...

证券之星消息，12月15日大博医疗发生大宗交易，交易数据如下： 大宗交易成交价格47元，相对当日收盘价折价3.96%，成交520万股，成交金额24440万元，买方营业部 为中信证券股份有限公司厦门分公司，卖方营业部为中信证券股份有限公司厦门分公司。 近三个月该股共发生2笔大宗交易，合计成交7.17万手，折价成交2笔。该股近期无解禁股上市。 该股近半年内有股东持股变动，合计净减持196.8万股，股东增减持明细如下表： 该股最近90天内共有1家机构给出评级，买入评级1家。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年12月15日收盘，大博医疗(002901)报收于48.94元，上涨4.68%，换手率1.3%，成交量3.75万 手，成交额1.83亿元。 ...